Phase II/ Phase III

Harbour BioMed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange

Lead Product(s): Batoclimab

Therapeutic Area: Immunology Product Name: HBM9161

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: BlackRock Fund

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Public Offering December 17, 2020

Details:

Net proceeds to be used in development of company's three anchor products: Batoclimab, tanfanercept, and HBM4003, to fund ongoing and planned clinical trials, and potential commercialization of other drug candidates in the Company’s pipeline.

Pharming

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Pharming Receives Orphan Drug Designation from EC for Leniolisib for the Treatment of Activated Phosphoinositide 3-Kinase Delta Syndrome

Lead Product(s): Leniolisib

Therapeutic Area: Immunology Product Name: CDZ173

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2020

Details:

Leniolisib is a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor with immunomodulating and potentially anti-neoplastic activities. Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate (PIP3).